Cargando…
Advances in targeted therapy for malignant lymphoma
The incidence of lymphoma has gradually increased over previous decades, and it ranks among the ten most prevalent cancers worldwide. With the development of targeted therapeutic strategies, though a subset of lymphoma patients has become curable, the treatment of refractory and relapsed diseases re...
Autores principales: | Wang, Li, Qin, Wei, Huo, Yu-Jia, Li, Xiao, Shi, Qing, Rasko, John E. J., Janin, Anne, Zhao, Wei-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058622/ https://www.ncbi.nlm.nih.gov/pubmed/32296035 http://dx.doi.org/10.1038/s41392-020-0113-2 |
Ejemplares similares
-
Tissue Factor-Targeted “O(2)-Evolving” Nanoparticles for Photodynamic Therapy in Malignant Lymphoma
por: Li, Ziying, et al.
Publicado: (2020) -
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors
por: Zheng, Zhong, et al.
Publicado: (2014) -
Genetic lesions and targeted therapy in Hodgkin lymphoma
por: Li, Zhe, et al.
Publicado: (2023) -
A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression
por: Sun, Rui, et al.
Publicado: (2020) -
Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy
por: Zhao, Xia, et al.
Publicado: (2013)